In the field of precision medicine, Dr Amy Abernethy has been a thought leader for over a decade, doing prominent early work on levels of evidence for off-label oncology drugs. She was Principal Deputy Commissioner of FDA for the last several years. Having stepped down from that role in April 2021, she's now announced to join VERILY, on a team that includes former FDA head (and Duke colleague) Robert Califf.
See article at Endpoints here. Healthcare Dive here. See press release here. Dr. Abernethy will be President of Clinical Research at Verily. See a review of her FDA work here, at FOCR.
See an article by Miksad and Abernethy on RWE here, written while at Flatiron.
